Trader sentiment on Encore Medical's (EMI) IPO closing market cap remains closely contested, with sub-$45 million (39.5%) edging out "No IPO before June 2026" (35.5%), reflecting uncertainty over execution risks and valuation amid weak fundamentals. Recent S-1/A amendments through early April 2026 confirm progress toward the April 22 pricing target for 3 million shares at $5.00, implying a ~$48 million post-money valuation on ~9.7 million fully diluted shares outstanding. However, persistent net losses ($1.8 million in 2024), modest revenue ($2.1 million), negative equity, and reliance on pending FDA approval for U.S. entry—coupled with competition from Abbott and Gore—temper demand expectations. Key swing factors include roadshow reception and SEC effectiveness, with first-day trading volatility pivotal ahead of clinical trial milestones.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado<45M 40%
Sem IPO antes de junho de 2026 36%
45M–50M 13%
50M–55M 8%
$11,738 Vol.
$11,738 Vol.
22 abr 2026
<45M
40%
45M–50M
13%
50M–55M
8%
Mais de 55M
5%
Sem IPO antes de junho de 2026
36%
<45M 40%
Sem IPO antes de junho de 2026 36%
45M–50M 13%
50M–55M 8%
$11,738 Vol.
$11,738 Vol.
22 abr 2026
<45M
$5,413 Vol.
40%
45M–50M
$1,392 Vol.
13%
50M–55M
$483 Vol.
8%
Mais de 55M
$651 Vol.
5%
Sem IPO antes de junho de 2026
$3,798 Vol.
36%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader sentiment on Encore Medical's (EMI) IPO closing market cap remains closely contested, with sub-$45 million (39.5%) edging out "No IPO before June 2026" (35.5%), reflecting uncertainty over execution risks and valuation amid weak fundamentals. Recent S-1/A amendments through early April 2026 confirm progress toward the April 22 pricing target for 3 million shares at $5.00, implying a ~$48 million post-money valuation on ~9.7 million fully diluted shares outstanding. However, persistent net losses ($1.8 million in 2024), modest revenue ($2.1 million), negative equity, and reliance on pending FDA approval for U.S. entry—coupled with competition from Abbott and Gore—temper demand expectations. Key swing factors include roadshow reception and SEC effectiveness, with first-day trading volatility pivotal ahead of clinical trial milestones.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Mercado Aberto: Apr 3, 2026, 7:59 PM ET
Volume
$11,738Data de Término
22 abr 2026Mercado Aberto
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader sentiment on Encore Medical's (EMI) IPO closing market cap remains closely contested, with sub-$45 million (39.5%) edging out "No IPO before June 2026" (35.5%), reflecting uncertainty over execution risks and valuation amid weak fundamentals. Recent S-1/A amendments through early April 2026 confirm progress toward the April 22 pricing target for 3 million shares at $5.00, implying a ~$48 million post-money valuation on ~9.7 million fully diluted shares outstanding. However, persistent net losses ($1.8 million in 2024), modest revenue ($2.1 million), negative equity, and reliance on pending FDA approval for U.S. entry—coupled with competition from Abbott and Gore—temper demand expectations. Key swing factors include roadshow reception and SEC effectiveness, with first-day trading volatility pivotal ahead of clinical trial milestones.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$11,738Data de Término
22 abr 2026Mercado Aberto
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Trader sentiment on Encore Medical's (EMI) IPO closing market cap remains closely contested, with sub-$45 million (39.5%) edging out "No IPO before June 2026" (35.5%), reflecting uncertainty over execution risks and valuation amid weak fundamentals. Recent S-1/A amendments through early April 2026 confirm progress toward the April 22 pricing target for 3 million shares at $5.00, implying a ~$48 million post-money valuation on ~9.7 million fully diluted shares outstanding. However, persistent net losses ($1.8 million in 2024), modest revenue ($2.1 million), negative equity, and reliance on pending FDA approval for U.S. entry—coupled with competition from Abbott and Gore—temper demand expectations. Key swing factors include roadshow reception and SEC effectiveness, with first-day trading volatility pivotal ahead of clinical trial milestones.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions